At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRFX PRF Technologies Ltd.
Closed 07-27 16:00:00 EDT
1.09
-0.04
-3.96%
盘后1.11
+0.02+1.83%
19:53 EDT
High1.20Low1.08Vol339.71K
Open1.13D1 Closing1.14Amplitude10.57%
Mkt Cap3.32MTradable Cap3.31MTotal Shares3.04M
T/O389.00KT/O Rate11.18%Tradable Shares3.04M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

PRF Technologies Readies Phase 2 Trial of LayerBio’s OcuRing-K Cataract Surgery Implant
Reuters  ·  07-27 20:48
PRF Technologies Readies Phase 2 Trial of LayerBio’s OcuRing-K Cataract Surgery Implant
PRF Technologies Expands Deepsolar Predict Platform to Optimize Battery Storage Revenue
Reuters  ·  07-15
PRF Technologies Expands Deepsolar Predict Platform to Optimize Battery Storage Revenue
PRF Technologies Announces Press Release Availability on Deepsolar Predict AI Platform Validation
Reuters  ·  07-08
PRF Technologies Announces Press Release Availability on Deepsolar Predict AI Platform Validation
PRF Technologies Says PRF-110 Showed Comparable Efficacy to Zynrelef in Preclinical Study
MT Newswires Live  ·  06-25
PRF Technologies Says PRF-110 Showed Comparable Efficacy to Zynrelef in Preclinical Study
PRF Technologies announces expanded results from PRF-110 study
TIPRANKS  ·  06-25
PRF Technologies announces expanded results from PRF-110 study
PRF Technologies Rises as Animal Study Shows Pain Drug Matches Approved Rival
Reuters  ·  06-25
PRF Technologies Rises as Animal Study Shows Pain Drug Matches Approved Rival
PRF Technologies Reports Expanded Preclinical Head-to-head Data for Prf-110 vs Zynrelef in Porcine Pain Model
Reuters  ·  06-25
PRF Technologies Reports Expanded Preclinical Head-to-head Data for Prf-110 vs Zynrelef in Porcine Pain Model
Prf Technologies - to Advance Prf-110 with Additional Studies
THOMSON REUTERS  ·  06-25
Prf Technologies - to Advance Prf-110 with Additional Studies
Prf Technologies Reports Expanded Preclinical Results for Prf-110 in Head-to-head Comparison with Approved Benchmark
THOMSON REUTERS  ·  06-25
Prf Technologies Reports Expanded Preclinical Results for Prf-110 in Head-to-head Comparison with Approved Benchmark
PRF Technologies files to sell 7.5M ordinary shares for holders
TIPRANKS  ·  06-23
PRF Technologies files to sell 7.5M ordinary shares for holders
Prf Technologies: Enters Purchase Agreement With Yorkville; May Sell Shares of up to $15 Mln - SEC Filing
THOMSON REUTERS  ·  06-19
Prf Technologies: Enters Purchase Agreement With Yorkville; May Sell Shares of up to $15 Mln - SEC Filing
PRF Technologies announces unregistered standby equity deal for up to $15 million shares with Yorkville
Reuters  ·  06-19
PRF Technologies announces unregistered standby equity deal for up to $15 million shares with Yorkville
Top Premarket Decliners
MT Newswires Live  ·  06-16
Top Premarket Decliners
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:51 PM
Reuters  ·  06-16
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:51 PM
Consumer Tech News (May 25-29): Dell, IBM, CrowdStrike, Meta Lead Big Tech AI Push
Benzinga  ·  05-31
Consumer Tech News (May 25-29): Dell, IBM, CrowdStrike, Meta Lead Big Tech AI Push
Why Is Penny Stock PRF Technologies (PRFX) Up Today?
TIPRANKS  ·  05-29
Why Is Penny Stock PRF Technologies (PRFX) Up Today?
Top Premarket Gainers
MT Newswires Live  ·  05-29
Top Premarket Gainers
PRF Technologies announces results from study comparing PRF-110 to Zynrelef
TIPRANKS  ·  05-26
PRF Technologies announces results from study comparing PRF-110 to Zynrelef
PRF Technologies says PRF-110 matches Zynrelef in 72-hour pig post-surgery pain study
Reuters  ·  05-26
PRF Technologies says PRF-110 matches Zynrelef in 72-hour pig post-surgery pain study
Prf Technologies Announces Prf-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
THOMSON REUTERS  ·  05-26
Prf Technologies Announces Prf-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study

Introduction

Company Name.
PRF Technologies Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Issue price:
--